SAN DIEGO– Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that two recent events relating to its OmniAb platform generated $4 million in combined payments due to Ligand…
Ligand Receives $4 Million from Expansion of Two OmniAb License Agreements Read More »
SAN DIEGO– Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into a worldwide license agreement with ABBA Therapeutics AG, a Swiss biotechnology company…
Ligand Enters Into OmniAb Platform License Agreement With ABBA Therapeutics Read More »
SAN DIEGO– Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into a worldwide license agreement with Tizona Therapeutics, Inc., an immunology company developing…
Ligand Enters Into OmniAb Platform License Agreement with Tizona Therapeutics Read More »
SAN DIEGO– Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into a worldwide license agreement with Emergent BioSolutions Inc. (NYSE: EBS), a global specialty…
Ligand Enters Into OmniAb Platform License Agreement with Emergent BioSolutions Read More »
SAN DIEGO & PALO ALTO, Calif.– Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and OMT, Inc. (Open Monoclonal Technology) announce the signing of agreements for Ligand to acquire OMT, Inc…
